TNF-alpha inhibitors

Restarting TNFi treatment after a break proves beneficial in psoriasisSwitching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
European Commission approves adalimumab for paediatric uveitisThe European Commission has approved adalimumab (Humira, AbbVie) as the first biologic treatment for chronic non-infectious anterior uveitis in paediatric patients from 2 years of age who have had an inadequate response to conventional therapy.
Biosimilar drugs appear comparable to brand-name counterpartsSystematic review provides comprehensive first look at TNF-alpha biosimilar treatments.
IL-6 inhibitor shows positive clinical benefit in RA patientsSarilumab may be an effective option for patients with moderately-to-severely active rheumatoid arthritis (RA) according to topline results from a new study.
Short-term systemic steroids for psoriasis efficacious despite ‘dogma’
Short-term systemic steroids for psoriasis efficacious despite ‘dogma’Data from a recently published study reveal systemic steroids are often the choice of therapy for clinicians based in the US who treat psoriasis, yet this practice is not endorsed in clinical practice guidelines.